Myeloid Therapeutics has raised $73m to support the continued clinical development of its lead cell therapy programme, MT-101, in Phase I/II trials for T cell lymphoma.
Led by Hatteras Investment Partners, the financing round has seen participation from existing investors, including 8VC, Alexandria Venture Investments and Newpath Partners, along with new investors Moore Strategic Ventures and ARCH Venture Partners.
Myeloid Therapeutics will use the funds to expedite the development of its first-in-class trophoblast cell-surface antigen 2 (TROP2)-FcA mRNA-LNP product, MT-302, into a Phase I/II trial for treating TROP2-expressing tumours.
MT-101 will be evaluated in the first-in-human, multicentre, open-label, multiple ascending dose Phase I/II IMAGINE trial to treat refractory or relapsed peripheral T cell lymphoma (PTCL) and cutaneous T cell lymphoma (CTCL) patients.
MT-302 is a TROP2-targeting in vivo chimeric antigen receptor (CAR) that has been designed to express in the myeloid compartment.
It showed monotherapy activity in a TROP2/TNBC model, which confirmed the programmed myeloid cells’ potency in the absence of T cells.
The financing will help to fast-track the development of other in vivo programming candidates into clinical trials.
Myeloid CEO Daniel Getts said: “Myeloid continues to make significant progress across all aspects of our business.
“We are pioneering the convergence of immunology and RNA science to build a clinical-stage portfolio of products, starting with the significant unmet needs of cancer patients.
“We are pleased that such high-quality investors have joined with us to accelerate this effort.”
Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.
Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.